New drug MTM-H-001 takes on tough blood cancers
NCT ID NCT07476378
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new drug called MTM-H-001 in 69 adults with B-cell blood cancers (like certain lymphomas and leukemias) that have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It's an open-label, single-arm trial, meaning everyone gets the drug and there's no placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MTM-H-001 Injection
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat B-cell blood cancers.
What could go wrong
This is a very early, small trial (69 people) with no control group. It mainly checks safety, so it may not show clear benefit or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Langfang, Hebei, 065000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••